1. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
- Author
-
Levis, Mark, Perl, Alexander, Schiller, Gary, Fathi, Amir, Roboz, Gail, Wang, Eunice, Altman, Jessica, Rajkhowa, Trivikram, Ando, Makoto, Suzuki, Takeaki, Subach, Ruth, Maier, Gary, Madden, Timothy, Johansen, Mary, Cheung, Kin, Kurman, Michael, and Smith, Catherine
- Subjects
Humans ,fms-Like Tyrosine Kinase 3 ,Leukemia ,Myeloid ,Acute ,Middle Aged ,Female ,Male ,Adult ,Aged ,Protein Kinase Inhibitors ,Recurrence ,Mutation ,Treatment Outcome ,Drug Resistance ,Neoplasm ,Aged ,80 and over ,Antineoplastic Agents ,Young Adult - Abstract
FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by tolerability problems when used in combination therapies. FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3, irreversibly inhibiting receptor signaling. It is effective against most FLT3 activating mutations, and, unlike other inhibitors, is minimally vulnerable to resistance induced by FLT3 ligand. We conducted a phase 1 dose escalation study of oral FF-10101 in patients with relapsed and/or refractory AML, the majority of whom harbored FLT3-activating mutations and/or had prior exposure to FLT3 inhibitors. Fifty-four participants enrolled in cohorts receiving doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID). The dose limiting toxicities were diarrhea and QT prolongation. Among 40 response-evaluable participants, the composite complete response rate was 10%, and the overall response rate (including partial responses) was 12.5%, including patients who had progressed on gilteritinib. Overall, 56% of participants had prior exposure to FLT3 inhibitors. The recommended phase 2 dose was 75 mg BID. FF-10101 potentially represents a next-generation advance in the management of FLT3-mutated AML. This trial was registered at www.ClinicalTrials.gov as #NCT03194685.
- Published
- 2024